## Mike Sharland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1737745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA). Expert Review of Anti-Infective Therapy, 2022, 20, 445-456.	4.4	4
2	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, 77, 448-456.	3.0	3
3	Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. The Lancet Child and Adolescent Health, 2022, 6, 49-59.	5.6	7
4	Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. Archives of Disease in Childhood, 2022, 107, 802-810.	1.9	9
5	Incidence and All-Cause Mortality Rates in Neonates Infected With Carbapenem Resistant Organisms. Frontiers in Tropical Diseases, 2022, 3, .	1.4	8
6	Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1193-1202.	6.0	53
7	Can the history of empiric antibiotic treatment for neonatal sepsis inform future global trials?. Clinical Microbiology and Infection, 2022, 28, 1313-1315.	6.0	1
8	Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infectious Diseases, The, 2021, 21, 107-115.	9.1	228
9	Fixedâ€dose combination antibiotics: The search for evidence using the example of ampicillin–cloxacillin. British Journal of Clinical Pharmacology, 2021, 87, 2996-2999.	2.4	7
10	High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries. PLoS ONE, 2021, 16, e0241899.	2.5	29
11	Variation in Target Attainment of Betaâ€Lactam Antibiotic Dosing Between International Pediatric Formularies. Clinical Pharmacology and Therapeutics, 2021, 109, 958-970.	4.7	5
12	Insufficient Stability of Clavulanic Acid in Widely Used Child-Appropriate Formulations. Antibiotics, 2021, 10, 225.	3.7	4
13	Association of Empiric Antibiotic Regimen Discordance With 30-Day Mortality in Neonatal and Pediatric Bloodstream Infection—A Global Retrospective Cohort Study. Pediatric Infectious Disease Journal, 2021, 40, 137-143.	2.0	27
14	Global Divergence of Antifungal Prescribing Patterns. Pediatric Infectious Disease Journal, 2021, 40, 327-332.	2.0	5
15	IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. Journal of Antimicrobial Chemotherapy, 2021, 76, 1855-1864.	3.0	21
16	Global antibiotic dosing strategies in hospitalised children: Characterising variation and implications for harmonisation of international guidelines. PLoS ONE, 2021, 16, e0252223.	2.5	3
17	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0029321.	3.2	12
18	Antibiotic Susceptibility, Virulome, and Clinical Outcomes in European Infants with Bloodstream Infections Caused by Enterobacterales. Antibiotics, 2021, 10, 706.	3.7	7

#	Article	IF	CITATIONS
19	The Urgent Need for Simple and Globally Applicable Quality Indicators of Optimal Prescribing for Children Using the Access, Watch, Reserve (AWaRe) System. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 845-846.	1.3	1
20	Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatric Drugs, 2021, 23, 465-484.	3.1	18
21	Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2021, 326, 1713.	7.4	57
22	Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT. Health Technology Assessment, 2021, 25, 1-72.	2.8	6
23	Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact. Clinical Infectious Diseases, 2020, 70, 1501-1508.	5.8	25
24	Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates. Pediatric Infectious Disease Journal, 2020, 39, 1032-1034.	2.0	4
25	β-Lactam antimicrobial Âpharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3625-3634.	3.0	13
26	2019 Community-acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1315-1316.	5.6	12
27	Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries. JAMA Network Open, 2020, 3, e1921124.	5.9	11
28	Appropriateness of Antibiotic Prescribing in United States Children's Hospitals: A National Point Prevalence Survey. Clinical Infectious Diseases, 2020, 71, e226-e234.	5.8	53
29	An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. Trials, 2020, 21, 329.	1.6	6
30	White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector—practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. Journal of Antimicrobial Chemotherapy, 2020, 75, ii42-ii51.	3.0	12
31	The current state of immunization against Gram-negative bacteria in children: a review of the literature. Current Opinion in Infectious Diseases, 2020, 33, 517-529.	3.1	5
32	A comparison of five paediatric dosing guidelines for antibiotics. Bulletin of the World Health Organization, 2020, 98, 406-412F.	3.3	12
33	Global sales of oral antibiotics formulated for children. Bulletin of the World Health Organization, 2020, 98, 458-466.	3.3	16
34	Measuring antibiotic availability and use in 20 low- and middle-income countries. Bulletin of the World Health Organization, 2020, 98, 177-187C.	3.3	29
35	Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe. Pediatric Infectious Disease Journal, 2020, 39, 1081-1087.	2.0	5
36	Intervention planning for Antibiotic Review Kit (ARK): a digital and behavioural intervention to safely review and reduce antibiotic prescriptions in acute and general medicine. Journal of Antimicrobial Chemotherapy, 2019, 74, 3362-3370.	3.0	24

#	Article	IF	CITATIONS
37	Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe. Journal of Antimicrobial Chemotherapy, 2019, 74, 3384-3389.	3.0	48
38	Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial. Trials, 2019, 20, 421.	1.6	7
39	Essential and forgotten antibiotics: An inventory in low- and middle-income countries. International Journal of Antimicrobial Agents, 2019, 54, 273-282.	2.5	9
40	Antibiotic prescriptions in Italian hospitalised children after serial point prevalence surveys (or) Tj ETQq0 0 0 rgB Pediatrics, 2019, 45, 127.	Overlock 2.6	2 10 Tf 50 62 8
41	Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. Lancet Infectious Diseases, The, 2019, 19, 1219-1234.	9.1	148
42	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. The Lancet Global Health, 2019, 7, e861-e871.	6.3	213
43	Hard to study, hard to treat: putting children at the centre of antibiotic research and development. Lancet Infectious Diseases, The, 2019, 19, 573-574.	9.1	1
44	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT). BMJ Open, 2019, 9, e029875.	1.9	10
45	Allâ€cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A populationâ€based study. Pharmacoepidemiology and Drug Safety, 2019, 28, 821-829.	1.9	8
46	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. Journal of Antimicrobial Chemotherapy, 2019, 74, 2128-2138.	3.0	33
47	Priority Needs for Conducting Pandemic-relevant Clinical Research With Children in Europe. Pediatric Infectious Disease Journal, 2019, 38, e82-e86.	2.0	2
48	Estimating global trends in total and childhood antibiotic consumption, 2011-2015. BMJ Global Health, 2019, 4, e001241.	4.7	47
49	Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view. BMJ Open, 2019, 9, e032592.	1.9	4
50	Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Annals of Clinical Microbiology and Antimicrobials, 2019, 18, 36.	3.8	45
51	Bacterial pathogens and resistance causing community acquired paediatric bloodstream infections in low- and middle-income countries: a systematic review and meta-analysis. Antimicrobial Resistance and Infection Control, 2019, 8, 207.	4.1	55
52	Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infectious Diseases, The, 2019, 19, 1278-1280.	9.1	106
53	Mathematical modelling for antibiotic resistance control policy: do we know enough?. BMC Infectious Diseases, 2019, 19, 1011.	2.9	37
54	Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert Review of Clinical Pharmacology, 2019, 12, 1099-1106.	3.1	6

#	Article	IF	CITATIONS
55	Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms. Pediatric Infectious Disease Journal, 2019, 38, 825-827.	2.0	4
56	Implementation of a Highly Accurate Rapid Point-of-Care Test for Group a Streptococcus Detection at a Large Pediatric Emergency Department in South London. Pediatric Infectious Disease Journal, 2019, 38, e183-e185.	2.0	2
57	Management of Invasive Fungal Disease in Neonates and Children. Pediatric Infectious Disease Journal, 2019, 38, S2-S6.	2.0	24
58	Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis. Pediatric Infectious Disease Journal, 2019, 38, 710-715.	2.0	9
59	Global Divergence From World Health Organization Treatment Guidelines for Neonatal and Pediatric Sepsis. Pediatric Infectious Disease Journal, 2019, 38, 1104-1106.	2.0	22
60	Pattern of Antimicrobial Resistance in Bloodstream Isolates From Chinese Neonates. Pediatric Infectious Disease Journal, 2019, 38, 600-604.	2.0	3
61	GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies – development and application in pediatric antibiotic studies. Expert Review of Clinical Pharmacology, 2019, 12, 1091-1098.	3.1	13
62	Scaling betaâ€lactam antimicrobial pharmacokinetics from early life to old age. British Journal of Clinical Pharmacology, 2019, 85, 316-346.	2.4	14
63	The use of polymyxins to treat carbapenem resistant infections in neonates and children. Expert Opinion on Pharmacotherapy, 2019, 20, 415-422.	1.8	35
64	Enterovirus and parechovirus meningitis in infants younger than 90 days old in the UK and Republic of Ireland: a British Paediatric Surveillance Unit study. Archives of Disease in Childhood, 2019, 104, 552-557.	1.9	48
65	Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infectious Diseases, The, 2019, 19, 67-75.	9.1	142
66	High Rates of Prescribing Antimicrobials for Prophylaxis in Children and Neonates: Results From the Antibiotic Resistance and Prescribing in European Children Point Prevalence Survey. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 143-151.	1.3	33
67	Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clinical Pharmacokinetics, 2019, 58, 39-52.	3.5	54
68	The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria. Journal of Medical Microbiology, 2019, 68, 711-719.	1.8	12
69	Unavailability of old antibiotics threatens effective treatment for common bacterial infections. Lancet Infectious Diseases, The, 2018, 18, 242-244.	9.1	13
70	Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016. International Journal of Infectious Diseases, 2018, 71, 20-24.	3.3	14
71	Classifying antibiotics in the WHO Essential Medicines List for optimal use—be AWaRe. Lancet Infectious Diseases, The, 2018, 18, 18-20	9.1	221
72	Management of children with multidrug-resistant sepsis in low-income and middle-income countries. The Lancet Child and Adolescent Health, 2018, 2, 8-10.	5.6	6

#	Article	IF	CITATIONS
73	Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000–2016: A Systematic Review and Meta-Analysis. Drugs, 2018, 78, 231-244.	10.9	12
74	Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
75	Surveillance for control of antimicrobial resistance. Lancet Infectious Diseases, The, 2018, 18, e99-e106.	9.1	235
76	World Society for Pediatric Infectious Diseases declaration on combating antimicrobial resistance in children. World Journal of Pediatrics, 2018, 14, 523-524.	1.8	4
77	Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis. Drugs, 2018, 78, 1593-1604.	10.9	4
78	Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children. Paediatrics and International Child Health, 2018, 38, S3-S15.	1.0	102
79	Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. Paediatrics and International Child Health, 2018, 38, S66-S75.	1.0	72
80	Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. Journal of Antimicrobial Chemotherapy, 2018, 73, 1908-1916.	3.0	49
81	Antibiotic usage in Chinese children: a point prevalence survey. World Journal of Pediatrics, 2018, 14, 335-343.	1.8	22
82	Using risk adjustment to improve the interpretation of global inpatient pediatric antibiotic prescribing. PLoS ONE, 2018, 13, e0199878.	2.5	5
83	Potential for reducing inappropriate antibiotic prescribing in English primary care. Journal of Antimicrobial Chemotherapy, 2018, 73, ii36-ii43.	3.0	169
84	DeNIS collaboration: setting the future research agenda. The Lancet Global Health, 2017, 5, e36.	6.3	1
85	Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infectious Diseases, The, 2017, 17, 381-389.	9.1	132
86	Fifteen-minute consultation: the complexities of empirical antibiotic selection for serious bacterial infections—a practical approach. Archives of Disease in Childhood: Education and Practice Edition, 2017, 102, 117-123.	0.5	7
87	What do I need to know about penicillin antibiotics?. Archives of Disease in Childhood: Education and Practice Edition, 2017, 102, 44-50.	0.5	8
88	What do I need to know about aminoglycoside antibiotics?. Archives of Disease in Childhood: Education and Practice Edition, 2017, 102, 89-93.	0.5	59
89	Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?. British Journal of Clinical Pharmacology, 2017, 83, 777-790.	2.4	88
90	Intensive Care Admissions for Children With Enterovirus and Human Parechovirus Infections in the United Kingdom and The Republic of Ireland, 2010–2014. Pediatric Infectious Disease Journal, 2017, 36, 339-342.	2.0	13

#	Article	IF	CITATIONS
91	Pointâ€ofâ€care tests for infectious diseases: barriers to implementation across three London teaching hospitals. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 1192-1195.	1.5	5
92	Predictors of fever-related admissions to a paediatric assessment unit, ward and reattendances in a South London emergency department: the CABIN 2 study. Archives of Disease in Childhood, 2017, 102, 22-28.	1.9	18
93	Surveillance Systems from Public Health Institutions and Scientific Societies for Antimicrobial Resistance and Healthcare-Associated Infections in Europe (SUSPIRE): protocol for a systematic review. BMJ Open, 2017, 7, e014538.	1.9	4
94	The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Drugs, 2017, 77, 941-950.	10.9	12
95	Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment. Current Opinion in Infectious Diseases, 2017, 30, 281-288.	3.1	61
96	High Reported Rates of Antimicrobial Resistance in Indian Neonatal and Pediatric Blood Stream Infections. Journal of the Pediatric Infectious Diseases Society, 2017, 6, e62-e68.	1.3	36
97	Did the accuracy of oral amoxicillin dosing of children improve after British National Formulary dose revisions in 2014? National cross-sectional survey in England. BMJ Open, 2017, 7, e016363.	1.9	4
98	Tackling antimicrobial resistance in neonatal sepsis. The Lancet Global Health, 2017, 5, e1066-e1068.	6.3	43
99	Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open, 2017, 7, e016293.	1.9	16
100	Urinary Tract Infection Antibiotic Trial Study Design: A Systematic Review. Pediatrics, 2017, 140, .	2.1	5
101	Congenital Cytomegalovirus. Pediatric Infectious Disease Journal, 2017, 36, 1205-1213.	2.0	181
102	The ethics of setting national antibiotic policies using financial incentives. British Journal of General Practice, 2017, 67, 419-420.	1.4	4
103	Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection. Journal of Medical Virology, 2017, 89, 502-507.	5.0	8
104	Serious bacterial infections in neonates: improving reporting and case definitions. International Health, 2017, 9, 148-155.	2.0	6
105	Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016. Antibiotics, 2017, 6, 19.	3.7	42
106	A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study. Antibiotics, 2017, 6, 9.	3.7	15
107	Antibiotic resistance has a language problem. Nature, 2017, 545, 23-25.	27.8	74
108	How do the epidemiology of paediatric methicillin-resistant Staphylococcus aureus and methicillin-susceptible Staphylococcus aureus bacteraemia differ?. Journal of Medical Microbiology, 2017, 66, 737-743.	1.8	3

#	Article	IF	CITATIONS
109	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. Health Technology Assessment, 2017, 21, 1-164.	2.8	19
110	Antibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? Data from the ARPEC Project. PLoS ONE, 2016, 11, e0154662.	2.5	52
111	Prevention and treatment of mother-to-child transmission of syphilis. Current Opinion in Infectious Diseases, 2016, 29, 268-274.	3.1	21
112	Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infectious Diseases, The, 2016, 16, e178-e189.	9.1	14
113	Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood Community Antibiotic Prescribing. Pediatric Infectious Disease Journal, 2016, 35, 1317-1323.	2.0	50
114	Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK. BMJ Open, 2016, 6, e012675.	1.9	56
115	Neonatal gram-negative infections, antibiotic susceptibility and clinical outcome: an observational study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F507-F512.	2.8	9
116	Fifteen-minute consultation: diagnosis and management of congenital CMV. Archives of Disease in Childhood: Education and Practice Edition, 2016, 101, 232-235.	0.5	13
117	Appropriate surveillance methodology for assessing childhood antibiotic resistance: where do we stand?. Future Microbiology, 2016, 11, 1109-1112.	2.0	1
118	Healthcare-Associated Infections in Pediatric and Neonatal Intensive Care Units: Impact of Underlying Risk Factors and Antimicrobial Resistance on 30-Day Case-Fatality in Italy and Brazil. Infection Control and Hospital Epidemiology, 2016, 37, 1302-1309.	1.8	36
119	Preemptive Screening Strategies to Identify Postnatal CMV Diseases on the Neonatal Unit. Pediatric Infectious Disease Journal, 2016, 35, 1148-1150.	2.0	6
120	Vancomycin toxicity in neonates. Current Opinion in Infectious Diseases, 2016, 29, 237-247.	3.1	50
121	Antibiotic preferences for childhood pneumonia vary by physician type and European region. ERJ Open Research, 2016, 2, 00001-2016.	2.6	1
122	Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 2016, 60, 4869-4877.	3.2	51
123	The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. Journal of Antimicrobial Chemotherapy, 2016, 71, 1106-1117.	3.0	238
124	Frontline Clinician Knowledge of Antimicrobial Prescribing in an Academic Tertiary Children's Hospital: A Point Prevalence Study: Table 1 Journal of the Pediatric Infectious Diseases Society, 2016, 5, 462-464.	1.3	0
125	International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet, The, 2016, 387, 296-307.	13.7	114
126	Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data. Journal of Antimicrobial Chemotherapy, 2016, 71, 794-802.	3.0	25

#	Article	IF	CITATIONS
127	A time for action: antimicrobial resistance needs global response. Bulletin of the World Health Organization, 2016, 94, 558-558A.	3.3	54
128	The global threat of antimicrobial resistance ―The need for standardized surveillance tools to define burden and develop interventions. Jornal De Pediatria (Versão Em Português), 2015, 91, 410-412.	0.2	0
129	Antibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children's Hospitals Varies Substantially from Adult Surveillance Data in Europe. Pediatric Infectious Disease Journal, 2015, 34, 734-741.	2.0	60
130	Neonatal infection: a major burden with minimal funding. The Lancet Global Health, 2015, 3, e669-e670.	6.3	10
131	Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. Journal of Antimicrobial Chemotherapy, 2015, 70, 279-285.	3.0	23
132	The global threat of antimicrobial resistance - The need for standardized surveillance tools to define burden and develop interventions. Jornal De Pediatria, 2015, 91, 410-412.	2.0	15
133	Qualitative Review of Web-Based Professional Education on Antibiotic Prescribing for Children: 10 Million Hits, but Only 10 Good Web Sites. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 159-162.	1.3	1
134	Improving antibiotic prescribing for children in the resourceâ€poor setting. British Journal of Clinical Pharmacology, 2015, 79, 446-455.	2.4	38
135	Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England. Journal of Infection, 2015, 71, 428-436.	3.3	44
136	Impact of UK Primary Care Policy Reforms on Short-Stay Unplanned Hospital Admissions for Children With Primary Care-Sensitive Conditions. Annals of Family Medicine, 2015, 13, 214-220.	1.9	28
137	Tonsillectomy among children with low baseline acute throat infection consultation rates in UK general practices: a cohort study. BMJ Open, 2015, 5, e006686-e006686.	1.9	6
138	Evaluating the feasibility of integrating salivary testing for congenital CMV into the Newborn Hearing Screening Programme in the UK. European Journal of Pediatrics, 2015, 174, 1117-1121.	2.7	21
139	The current and future roles of neonatal infection surveillance programmes in combating antimicrobial resistance. Early Human Development, 2015, 91, 613-618.	1.8	25
140	Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respiratory Medicine,the, 2015, 3, 888-900.	10.7	229
141	First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F501-F506.	2.8	47
142	How to use vancomycin optimally in neonates: remaining questions. Expert Review of Clinical Pharmacology, 2015, 8, 635-648.	3.1	28
143	Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine, 2015, 33, 5072-5079.	3.8	94
144	Targeted empiric antibiotic therapy for children with non-oncological comorbidities and community-onset invasive bacterial infections. Journal of Infection, 2015, 71, 294-301.	3.3	2

#	Article	IF	CITATIONS
145	Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 11-20.	1.3	97
146	Reported Rates of Diarrhea Following Oral Penicillin Therapy in Pediatric Clinical Trials. Journal of Pediatric Pharmacology and Therapeutics, 2015, 20, 90-104.	0.5	25
147	Think Hickam's Dictum not Occam's Razor in paediatric HIV. BMJ Case Reports, 2014, 2014, bcr2013202029-bcr2013202029.	0.5	1
148	Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, F230-F236.	2.8	55
149	Aminoglycoside toxicity in neonates: something to worry about?. Expert Review of Anti-Infective Therapy, 2014, 12, 319-331.	4.4	57
150	Invasive bacterial and fungal infections in paediatric patients with cancer: Incidence, risk factors, aetiology and outcomes in a UK regional cohort 2009–2011. Pediatric Blood and Cancer, 2014, 61, 1239-1245.	1.5	17
151	Epidemiology and Clinical Outcomes of Multidrug-resistant, Gram-negative Bloodstream Infections in a European Tertiary Pediatric Hospital During a 12-month Period. Pediatric Infectious Disease Journal, 2014, 33, 929-932.	2.0	66
152	Incidence, Spectrum and Outcome of Immune Reconstitution Syndrome in HIV-infected Children after Initiation of Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2014, 33, 953-958.	2.0	19
153	Antibiotic prescribing in the paediatric emergency department and the impact of education. Journal of Paediatrics and Child Health, 2014, 50, 932-933.	0.8	3
154	Very low rates of culture-confirmed invasive bacterial infections in a prospective 3-year population-based surveillance in Southwest London. Archives of Disease in Childhood, 2014, 99, 526-531.	1.9	23
155	Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004–11: an observational study. Lancet Infectious Diseases, The, 2014, 14, 301-307.	9.1	105
156	Current management of late onset neonatal bacterial sepsis in five European countries. European Journal of Pediatrics, 2014, 173, 997-1004.	2.7	34
157	Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Archives of Disease in Childhood, 2014, 99, 469-473.	1.9	32
158	Seven-fold increase in viral meningo-encephalitis reports in England and Wales during 2004–2013. Journal of Infection, 2014, 69, 326-332.	3.3	40
159	Changing Indications and Socio-Demographic Determinants of (Adeno)Tonsillectomy among Children in England – Are They Linked? A Retrospective Analysis of Hospital Data. PLoS ONE, 2014, 9, e103600.	2.5	17
160	Oral penicillin prescribing for children in the UK: a comparison with <i>BNF for Children</i> age-band recommendations. British Journal of General Practice, 2014, 64, e217-e222.	1.4	12
161	Risk Factors for Hospital Admission with RSV Bronchiolitis in England: A Population-Based Birth Cohort Study. PLoS ONE, 2014, 9, e89186.	2.5	156
162	New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000—Why aren't we doing better?. International Journal of Antimicrobial Agents, 2013, 42, 99-118.	2.5	19

#	Article	IF	CITATIONS
163	Clinical trials in neonatal sepsis. Journal of Antimicrobial Chemotherapy, 2013, 68, 2733-2745.	3.0	41
164	Managing and preventing outbreaks of Gram-negative infections in UK neonatal units: TableÂ1. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2013, 98, F549-F553.	2.8	42
165	A systematic review of strategies for reporting of neonatal hospital-acquired bloodstream infections. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2013, 98, F518-F523.	2.8	15
166	Trends in paediatric nosocomial bacteraemia in a London tertiary hospital. Acta Paediatrica, International Journal of Paediatrics, 2013, 102, 1005-1009.	1.5	9
167	Antimicrobial stewardship: English Surveillance Programme for Antimicrobial Utilization and Resistance (ESPAUR). Journal of Antimicrobial Chemotherapy, 2013, 68, 2421-2423.	3.0	60
168	Measuring antibiotic prescribing in hospitalised children in resourceâ€poor countries: A systematic review. Journal of Paediatrics and Child Health, 2013, 49, 185-192.	0.8	12
169	Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Seminars in Fetal and Neonatal Medicine, 2013, 18, 28-34.	2.3	59
170	The new UK antimicrobial resistance strategy and action plan. BMJ, The, 2013, 346, f1601-f1601.	6.0	25
171	The Novel Antiviral Pipeline to Treat Severe Neonatal Viral Infections. Pediatric Infectious Disease Journal, 2013, 32, 682-683.	2.0	0
172	Neonatal and Pediatric Antimicrobial Stewardship Programs in Europe—Defining the Research Agenda. Pediatric Infectious Disease Journal, 2013, 32, e456-e465.	2.0	22
173	New traffic light system guides evaluation of febrile children. The Prescriber, 2013, 24, 7-7.	0.3	0
174	Clinical and Microbiologic Features Guiding Treatment Recommendations for Brain Abscesses in Children. Pediatric Infectious Disease Journal, 2013, 32, 129-135.	2.0	67
175	The Antibiotic Resistance and Prescribing in European Children Project. Pediatric Infectious Disease Journal, 2013, 32, e242-e253.	2.0	143
176	The Epidemiology of Neonatal and Pediatric Candidemia in England and Wales, 2000–2009. Pediatric Infectious Disease Journal, 2013, 32, 23-26.	2.0	33
177	Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis. BMJ Case Reports, 2013, 2013, bcr2012008207-bcr2012008207.	0.5	6
178	Neonatal sepsis – many blood samples, few positive cultures: implications for improving antibiotic prescribing. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2012, 97, 487-488.	2.8	28
179	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Medicine, 2012, 9, e1001194.	8.4	145
180	Significantly increasing hospital admissions for acute throat infections among children in England: is this related to tonsillectomy rates?. Archives of Disease in Childhood, 2012, 97, 1064-1068.	1.9	18

#	Article	IF	CITATIONS
181	Improving antibiotic prescribing in neonatal units: time to act: Table 1. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2012, 97, F141-F146.	2.8	64
182	Surveillance swabbing for MRSA on neonatal intensive care units – is weekly nasal swabbing the best option?. Journal of Infection Prevention, 2012, 13, 120-124.	0.9	2
183	Antibiotic dosing in children in Europe. Current Opinion in Infectious Diseases, 2012, 25, 235-242.	3.1	28
184	Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. Journal of Antimicrobial Chemotherapy, 2012, 67, 1278-1286.	3.0	65
185	Exploring the Epidemiology of Hospital-Acquired Bloodstream Infections in Children in England (January 2009–March 2010) by Linkage of National Hospital Admissions and Microbiological Databases. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 284-292.	1.3	14
186	Do We Know When, What and For How Long to Treat?. Pediatric Infectious Disease Journal, 2012, 31, e78-e85.	2.0	93
187	Primary care of children: the unique role of GPs. British Journal of General Practice, 2012, 62, 340-341.	1.4	11
188	Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start SmartThen Focus. Journal of Antimicrobial Chemotherapy, 2012, 67, i51-i63.	3.0	201
189	Antibiotic prescribing for upper respiratory infections: European primary paediatricians' knowledge, attitudes and practice. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 935-940.	1.5	38
190	Ganciclovir treatment in children: evidence of subtherapeutic levels. International Journal of Antimicrobial Agents, 2011, 37, 445-448.	2.5	31
191	Antiviral Therapy of CMV Disease in Children. Advances in Experimental Medicine and Biology, 2011, 697, 243-260.	1.6	24
192	Dosing of oral penicillins in children: is big child=half an adult, small child=half a big child, baby=half a small child still the best we can do?. BMJ: British Medical Journal, 2011, 343, d7803-d7803.	2.3	17
193	THE CONTRIBUTION OF INFECTIONS TO NEONATAL DEATHS IN ENGLAND AND WALES. Pediatric Infectious Disease Journal, 2011, 30, 345-347.	2.0	33
194	Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a â€~right' choice?. Current Opinion in Infectious Diseases, 2011, 24, 163-171.	3.1	32
195	Using antibiotics responsibly: right drug, right time, right dose, right duration. Journal of Antimicrobial Chemotherapy, 2011, 66, 2441-2443.	3.0	101
196	High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. Aids, 2010, 24, 2416-2418.	2.2	46
197	Risk–benefit analysis of restricting antimicrobial prescribing in children: what do we really know?. Current Opinion in Infectious Diseases, 2010, 23, 242-248.	3.1	45
198	Off-label antibiotic use in children in three European countries. European Journal of Clinical Pharmacology, 2010, 66, 919-927.	1.9	45

#	Article	IF	CITATIONS
199	Response to Gandhi etÂal., Management of congenital cytomegalovirus infection. Acta Paediatrica, International Journal of Paediatrics, 2010, 99, 1445-1445.	1.5	0
200	Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax, 2010, 65, 770-774.	5.6	113
201	The changing aetiology of paediatric bacteraemia in England and Wales, 1998–2007. Journal of Medical Microbiology, 2010, 59, 213-219.	1.8	32
202	Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control study. Aids, 2010, 24, 525-534.	2.2	39
203	Increasing Skin Infections andStaphylococcus aureusComplications in Children, England, 1997–2006. Emerging Infectious Diseases, 2010, 16, 530-533.	4.3	15
204	Continuing Impact of Infectious Diseases on Childhood Deaths in England and Wales, 2003–2005. Pediatric Infectious Disease Journal, 2010, 29, 310-313.	2.0	37
205	Vancomycin may not be necessary. BMJ: British Medical Journal, 2010, 341, c4704-c4704.	2.3	5
206	Young People in the United Kingdom and Ireland with Perinatally Acquired HIV: The Pediatric Legacy For Adult Services. AIDS Patient Care and STDs, 2009, 23, 159-166.	2.5	76
207	18 November and beyond: observations on the EU Antibiotic Awareness Day. Journal of Antimicrobial Chemotherapy, 2009, 63, 633-635.	3.0	10
208	Effect of Antibiotics for Otitis Media on Mastoiditis in Children: A Retrospective Cohort Study Using the United Kingdom General Practice Research Database. Pediatrics, 2009, 123, 424-430.	2.1	112
209	Use of stored dried blood spots for retrospective diagnosis of congenital CMV. Journal of Medical Virology, 2009, 81, 1394-1398.	5.0	54
210	Infectionâ€related mortality in children with malignancy in England and Wales, 2003–2005. Pediatric Blood and Cancer, 2009, 53, 371-374.	1.5	6
211	PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIVâ€1 infection. HIV Medicine, 2009, 10, 591-613.	2.2	135
212	Diagnosis and treatment of aspergillosis in children. Expert Review of Anti-Infective Therapy, 2009, 7, 461-472.	4.4	22
213	Inhaled corticosteroids after respiratory syncytial virus infection. BMJ: British Medical Journal, 2009, 338, b164-b164.	2.3	1
214	Increasing Short-Stay Unplanned Hospital Admissions among Children in England; Time Trends Analysis '97–â€~06. PLoS ONE, 2009, 4, e7484.	2.5	76
215	Chemokine-receptor upregulation and disease severity in Respiratory Syncytial Virus infection. Clinical Immunology, 2008, 128, 85-93.	3.2	10
216	The European Union Antibiotic Awareness Day: the paediatric perspective. Archives of Disease in Childhood, 2008, 93, 909-910.	1.9	24

#	Article	IF	CITATIONS
217	Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?. Current Opinion in Infectious Diseases, 2008, 21, 258-262.	3.1	50
218	Early diagnosis of tuberculosis using an INF-Î <sup>3</sup> assay in a child with HIV-1 infection and a very low CD4 count. Scandinavian Journal of Infectious Diseases, 2007, 39, 919-921.	1.5	5
219	RSV-infected airway epithelial cells cause biphasic up-regulation of CCR1 expression on human monocytes. Journal of Leukocyte Biology, 2007, 81, 1487-1495.	3.3	16
220	Prevalence of nasopharyngeal carriage of pneumococcus in preschool children attending day care in London. Archives of Disease in Childhood, 2007, 92, 1073-1076.	1.9	13
221	The use of antibacterials in children: a report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Paediatric Subgroup. Journal of Antimicrobial Chemotherapy, 2007, 60, i15-i26.	3.0	57
222	Morbidity, Mortality, and Response to Treatment by Children in the United Kingdom and Ireland with Perinatally Acquired HIV Infection during 1996-2006: Planning for Teenage and Adult Care. Clinical Infectious Diseases, 2007, 45, 918-924.	5.8	194
223	Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection. Expert Review of Anti-Infective Therapy, 2007, 5, 415-425.	4.4	7
224	Ganciclovir therapy for neonates with congenital cytomegalovirus infection. European Journal of Pediatrics, 2007, 166, 633-634.	2.7	3
225	Advances in the antiviral therapy of herpes virus infection in children. Expert Review of Anti-Infective Therapy, 2006, 4, 1005-1020.	4.4	12
226	Outcomes for Human Immunodeficiency Virus-1-Infected Infants in the United Kingdom and Republic of Ireland in the Era of Effective Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2006, 25, 420-426.	2.0	60
227	Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ: British Medical Journal, 2006, 332, 1183-1187.	2.3	88
228	Neonatal adrenal abscess revisited: the importance of raised inflammatory markers. Annals of Tropical Paediatrics, 2005, 25, 63-66.	1.0	6
229	Genetic Variation at theIL10Gene Locus Is Associated with Severity of Respiratory Syncytial Virus Bronchiolitis. Journal of Infectious Diseases, 2005, 191, 1705-1709.	4.0	72
230	Prevention of respiratory syncytial virus infection in infants. BMJ: British Medical Journal, 2004, 328, 1026-1027.	2.3	20
231	Use of serial maternal urine cytomegalovirus PCR to detect primary CMV infection in seronegative pregnant women. Journal of Virological Methods, 2004, 119, 31-35.	2.1	12
232	Haplotype mapping of the bronchiolitis susceptibility locus near IL8. Human Genetics, 2004, 114, 272-279.	3.8	59
233	Triple Nucleoside Reverse Transcriptase Inhibitor Therapy in??Children. Paediatric Drugs, 2004, 6, 147-159.	3.1	17
234	Response to highly active antiretroviral therapy varies with age. Aids, 2004, 18, 1915-1924.	2.2	111

#	Article	IF	CITATIONS
235	Variants of the Chemokine Receptor CCR5 Are Associated with Severe Bronchiolitis Caused by Respiratory Syncytial Virus. Journal of Infectious Diseases, 2003, 188, 904-907.	4.0	70
236	Nevirapine use in HIV-1-infected children. Aids, 2003, 17, 1639-1647.	2.2	45
237	Steroids Fail to Down-Regulate Respiratory Syncytial Virus-Induced IL-8 Secretion in Infants. Pediatric Research, 2002, 52, 368-372.	2.3	19
238	Cytomegalovirus treatment options in immunocompromised patients. Expert Opinion on Pharmacotherapy, 2001, 2, 1247-1257.	1.8	20
239	Preventing respiratory syncitial virus bronchiolitis. BMJ: British Medical Journal, 2001, 322, 62-63.	2.3	20
240	Influenza. Expert Opinion on Pharmacotherapy, 2000, 1, 367-375.	1.8	7
241	Current treatment options to prevent perinatal transmission of HIV. Expert Opinion on Pharmacotherapy, 2000, 1, 239-248.	1.8	3
242	Synergistic Upregulation of Interleukin-8 Secretion from Pulmonary Epithelial Cells by Direct and Monocyte-Dependent Effects of Respiratory Syncytial Virus Infection. Journal of Virology, 2000, 74, 8425-8433.	3.4	30
243	Pulmonary manifestations of pediatric HIV infection. Indian Journal of Pediatrics, 1999, 66, 895-904.	0.8	11
244	Immune reconstitution in HAART-treated children with AIDS. Lancet, The, 1998, 352, 577-578.	13.7	25